Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2018-03-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
独立董事2017年度述职报告（章金刚）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Report" and contains detailed statements from an independent director about their duties, attendance at board meetings, opinions on related party transactions, internal control evaluations, audit firm appointments, investment decisions, and profit distribution proposals for the year 2017. It references compliance with regulatory requirements and provides a comprehensive review of the director's activities and opinions during the year. The content is a detailed management report on governance and oversight activities rather than a full annual financial report or a simple announcement. It is not a certification or a brief announcement but a substantive report on management and board oversight activities. Therefore, the document best fits the category of Board/Management Information (MANG). The document length (4778 characters) and detailed content support this classification with high confidence.
2018-03-26 Chinese
关于为参股公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 华兰生物工程股份有限公司 regarding the provision of a guarantee for a bank loan to an affiliated company, 华兰基因工程有限公司. It includes details about the guarantee amount, the board's approval, independent directors' opinions, and compliance with regulatory guidelines. The document is relatively short (1486 characters) and serves as an official notice of a corporate action related to financing activities, specifically providing a guarantee. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities such as guarantees and loans.
2018-03-26 Chinese
关于用自有资金进行投资理财的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 华兰生物工程股份有限公司 regarding the company's decision to use up to 20 billion yuan of its own funds for investment and financial management. It details the investment purpose, amount, targets, approval procedures, risk control measures, and includes independent directors' opinions on the matter. The document is an announcement about a capital management decision rather than a financial report or earnings release. It does not contain financial statements or detailed financial data. The document length is short (1477 characters), and it is clearly an announcement of a financing-related activity (investment of own funds). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-03-26 Chinese
独立董事对公司相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion report on various company matters including related party transactions, external guarantees, internal control evaluation, appointment of the audit firm for the next year, investment and financing, profit distribution plan, guarantees for an associate company, and appointment of senior management. It references regulatory guidelines and laws related to independent directors and corporate governance. The document does not contain full financial statements or detailed financial results but provides independent opinions on governance and compliance matters. It is not an annual report, audit report, or earnings release. It is a governance-related document focusing on independent directors' opinions on company affairs and compliance with regulations. Therefore, the most appropriate classification is Board/Management Information (MANG), as it relates to board and management matters including appointments and opinions on company governance and related party transactions.
2018-03-26 Chinese
2017年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2017 Annual Report Summary" of 华兰生物工程股份有限公司, which indicates it is a summary of the full annual report. It contains detailed financial data for the year 2017, including revenue, net profit, assets, and shareholder information. It also discusses business operations, product lines, industry position, accounting policies, and management analysis. The length of the document (over 13,000 characters) and the presence of comprehensive financial and operational data confirm it is a substantive financial report rather than a brief announcement or presentation. The document is not a mere announcement of report publication, nor is it a certification or a regulatory filing. Therefore, it fits the definition of an Annual Report (10-K). FY 2017
2018-03-26 Chinese
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 华兰生物工程股份有限公司 covering the fiscal year from January 1, 2017 to December 31, 2017. It includes detailed auditor opinions, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters) and contains actual financial data and audit analysis, not just a certification or announcement. Therefore, the correct classification is Audit Report / Information (AR). FY 2017
2018-03-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.